Ponatinib (AP24534)

For research use only. Not for use in humans.

目录号：S1490

Molecular Weight(MW): 532.56

Ponatinib (AP24534)是一种新型有效的多靶点抑制剂，在无细胞试验中作用于Abl，PDGFRα，VEGFR2，FGFR1和Src，IC50分别为0.37 nM，1.1 nM，1.5 nM，2.2 nM和5.4 nM。Ponatinib (AP24534)可抑制自噬。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 819.31	现货
10mg	RMB 903.01	现货
50mg	RMB 3034.48	现货
200mg	RMB 7959.08	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Ponatinib (AP24534)发表文献95篇：

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(4):431-443

PubMed: 31543464 ( click the link to review the publication )

Nature, 2016, 30;534(7609):647-51.

PubMed: 27338794 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Nature, 2015, 10.1038/nature14329

PubMed: 25970250 ( click the link to review the publication )

Cancer Cell, 2014, 26(2):207-21

PubMed: 25065853 ( click the link to review the publication )

Cancer Cell, 2012, 22(5):656-67

PubMed: 23153538 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.32924

PubMed: 32064608 ( click the link to review the publication )

FASEB J, 2020, 34(3):3773-3791

PubMed: 31945226 ( click the link to review the publication )

Mol Cell Proteomics, 2020, 10.1074/mcp.RA119.001504

PubMed: 32102969 ( click the link to review the publication )

J Infect Dis, 2020, 3;jiaa295

PubMed: 32492702 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Front Pharmacol, 2020, 30;11:543

PubMed: 32425788 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2020, 1864(4):129507

PubMed: 31881245 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2020, 10.1007/s00280-019-04022-x

PubMed: 31901955 ( click the link to review the publication )

Commun Biol, 2020, 3(1):18

PubMed: 31925328 ( click the link to review the publication )

Cold Spring Harb Mol Case Stud, 2020, 1;6(2) pii: a004838

PubMed: 31980503 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-2779

PubMed: 31515463 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )
Protein Cell, 2019, 10(3):161-177

PubMed: 29667003 ( click the link to review the publication )

Br J Cancer, 2019, 120(6):612-620

PubMed: 30792533 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(11):1985-1996

PubMed: 31308077 ( click the link to review the publication )

FEBS J, 2019, 286(22):4443-4472

PubMed: 31155838 ( click the link to review the publication )

Front Oncol, 2019, 9:103

PubMed: 30931252 ( click the link to review the publication )

J Proteome Res, 2019, 18(1):522-534

PubMed: 30540191 ( click the link to review the publication )

Cell Cycle, 2019, 18(18):2307-2322

PubMed: 31349760 ( click the link to review the publication )

Transl Oncol, 2019, 12(9):1221-1228

PubMed: 31276961 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(1):189-199

PubMed: 29741440 ( click the link to review the publication )

Exp Dermatol, 2019, 10.1111/exd.14010

PubMed: 31338879 ( click the link to review the publication )

Clin Exp Pharmacol Physiol, 2019, 46(2):126-136

PubMed: 30251267 ( click the link to review the publication )

Leukemia, 2019, 33(8):1964-1977

PubMed: 30842608 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(8):1932-1943

PubMed: 29440177 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30572654 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1405-1415

PubMed: 29695637 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Respir Res, 2018, 19(1):120

PubMed: 29921306 ( click the link to review the publication )

Oncotarget, 2018, 9(100):37352-37366

PubMed: 30647837 ( click the link to review the publication )

Oncotarget, 2018, 9(65):32496-32506

PubMed: 30197758 ( click the link to review the publication )

Sci Adv, 2018, 4(11):eaau0731

PubMed: 30417093 ( click the link to review the publication )

Sci Transl Med, 2017, 14;9(394):eaah6144

PubMed: 28615362 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28199182 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):8

PubMed: 28069043 ( click the link to review the publication )
Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-17-0008

PubMed: 28500237 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10-:2130-2143

PubMed: 28751539 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1729-1738

PubMed: 28619758 ( click the link to review the publication )

Sci Rep, 2017, 7(1-:5519

PubMed: 28717217 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(6):1455-1467

PubMed: 27733071 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15219

PubMed: 29123157 ( click the link to review the publication )

Gut, 2016, 10.1136/gutjnl-2015-310382

PubMed: 26953272 ( click the link to review the publication )

Blood, 2016, 28;127(17):2131-43

PubMed: 26864341 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1273-1281

PubMed: 27068398 ( click the link to review the publication )

Leukemia, 2016, 30(7):1493-501

PubMed: 27044711 ( click the link to review the publication )

Cancer Sci, 2016, 107(2):140-8

PubMed: 26583567 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Oncotarget, 2016, 7(47):78083-78094

PubMed: 27801667 ( click the link to review the publication )

Tumour Biol, 2016, 37(2):2365-78

PubMed: 26373734 ( click the link to review the publication )

Genes Chromosomes Cancer, 2016, 55(1):60-8

PubMed: 26391436 ( click the link to review the publication )

Oncotarget, 2016, 7(31-:50161-50179

PubMed: 27367030 ( click the link to review the publication )

Sci Transl Med, 2015, 7(298):298ra119

PubMed: 26223302 ( click the link to review the publication )

Nat Commun, 2015, 6:7002

PubMed: 25926053 ( click the link to review the publication )

Leukemia, 2015, 29(5)

PubMed: 25394714 ( click the link to review the publication )

Leukemia, 2015, 29(12):2390-2

PubMed: 26108694 ( click the link to review the publication )

J Med Chem, 2015, 58(23):9228-37

PubMed: 26562217 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1767

PubMed: 25996294 ( click the link to review the publication )
Toxicol Sci, 2015, 143(1):147-55

PubMed: 25304212 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120841

PubMed: 25803811 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(2):133-44

PubMed: 24463606 ( click the link to review the publication )

Sci Transl Med, 2014, 6(261):261ra152

PubMed: 25378644 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )

Genome Biol, 2014, 15(8):428

PubMed: 25315765 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2092-103

PubMed: 24436473 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 10.1073/pnas.1321173111

PubMed: 24550512 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(10):2315-27

PubMed: 25053825 ( click the link to review the publication )

Structure, 2014, 22(12):1764-74

PubMed: 25465127 ( click the link to review the publication )

Oncol Rep, 2014, 31(4):1605-12

PubMed: 24481648 ( click the link to review the publication )

Thrombo Res, 2014, 135(1):155-60

PubMed: 25527332 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 446(1):54-60

PubMed: 24565842 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )

J Thorac Oncol, 2014, 9(9):1316-23

PubMed: 25122427 ( click the link to review the publication )

Harvard University, 2014, Rachel Grace Liao

PubMed: ( click the link to review the publication )

Clin Cancer Res, 2013, 19(6):1422-32

PubMed: 23319824 ( click the link to review the publication )

Cancer Res, 2013, 73(16):5195-205

PubMed: 23786770 ( click the link to review the publication )

Neoplasia, 2013, 15(8):975-88

PubMed: 23908597 ( click the link to review the publication )

Curr Cancer Drug Targets, 2012, 12(5):505-21

PubMed: 22483156 ( click the link to review the publication )

Exp Hematol, 2012, 41(4):335-45.e3

PubMed: 23287417 ( click the link to review the publication )

Mol Genet Metab, 2010, 100(4):309-15

PubMed: 20554235 ( click the link to review the publication )

产品安全说明书

Bcr-Abl抑制剂选择性比较

生物活性

产品描述

靶点

Abl ^[1] (Cell-free assay)	PDGFRα ^[1] (Cell-free assay)	VEGFR2 ^[1] (Cell-free assay)	FGFR1 ^[1] (Cell-free assay)	c-Src ^[1] (Cell-free assay)	点击更多
0.37 nM	1.1 nM	1.5 nM	2.2 nM	5.4 nM	点击更多

体外研究

Ponatinib是有效的可用于口服的多靶点激酶抑制剂，作用于野生型细胞,及T315I 突变细胞IC50分别为1.2和8.8nM。^[1] Ponatinib抑制Ba/F3衍生细胞系的增殖。^[2] Ponatinib作用于表达野生型或T315I突变型BCR-ABL的CML细胞系，有效抑制BCR-ABL调节的信号。Ponatinib阻断在细胞瘤筛选时产生抗性突变。^[3] Ponatinib也抑制VEGFR和FGFR家族激酶，在体外抑制FLT3, KIT, FGFR1,和PDGFRa激酶活性时IC50分别为13, 13, 2, 和1 nM.^[4]Ponatinib抑制全部4种RTKs磷酸化，存在剂量依赖性，IC50值为0.3到20 nM。然而，Ponatinib抑制表达野生型FLT3的RS4;11细胞时IC50>100 nM。

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
EoL-1-cell	MkXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml6wTWM2OD1yLkCwNFAxODB\|NUmg{txO	Mn:xV2FPT0WU
MV-4-11	NWPVfWVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPCNoxJUUN3ME2wMlAxODB7NU[g{txO	NYDR[nk6W0GQR1XS
MEG-01	Mk\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTJXGFOUUN3ME2wMlAxODF{ODFOwG0>	M3exeXNCVkeHUh?=
LAMA-84	NIC2VG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPzTWM2OD1yLkCwNFE3PSEQvF2=	MYDTRW5ITVJ?
CGTH-W-1	NU\wPZpIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3jO21jUUN3ME2wMlAxOTZ7IN88US=>	NUfQeGhqW0GQR1XS
KASUMI-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjoTWM2OD1yLkCwNlE4KM7:TR?=	NH7UfHVUSU6JRWK=
BE-13	Mn6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1riW2lEPTB;MD6wNFI2QSEQvF2=	NFe1eXVUSU6JRWK=
CTV-1	NWfRcJBoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPRVI5zUUN3ME2wMlAxPTJzIN88US=>	Mn21V2FPT0WU
NKM-1	NYTxNpF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV30PY9DUUN3ME2wMlAxPjV3IN88US=>	MWDTRW5ITVJ?
MONO-MAC-6	MkXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TMd2lEPTB;MD6wNFg{PyEQvF2=	MUPTRW5ITVJ?
A204	MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zOcGlEPTB;MD6wNVIyQCEQvF2=	MULTRW5ITVJ?
GDM-1	NUDZSWVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\BdZdPUUN3ME2wMlAyQDN\|IN88US=>	NGnkdVdUSU6JRWK=
AN3-CA	NFvnW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVG1e3UyUUN3ME2wMlAyQDd\|IN88US=>	MXTTRW5ITVJ?
BL-70	NHrWZ25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXuTWM2OD1yLkCyNVk6KM7:TR?=	NH;F[HZUSU6JRWK=
Daudi	NGfDbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HLcGlEPTB;MD6wNlU{PyEQvF2=	NFvwSYFUSU6JRWK=
KU812	MoHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnuTWM2OD1yLkCyPFQ5KM7:TR?=	MUHTRW5ITVJ?
KG-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjYZ4dGUUN3ME2wMlA{Ojl2IN88US=>	M3HXUXNCVkeHUh?=
DOHH-2	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1L3PWlEPTB;MD6wOFgxOyEQvF2=	MlzJV2FPT0WU
HuO9	M135dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn34TWM2OD1yLkC1OFQ5KM7:TR?=	M4TodXNCVkeHUh?=
EB2	Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\pTWM2OD1yLkC1OVc3KM7:TR?=	MmfwV2FPT0WU
G-402	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4H0NGlEPTB;MD6wOlM1OSEQvF2=	M1XWZnNCVkeHUh?=
SU-DHL-1	NUnxUW1wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTBwME[zO\|kh\|ryP	NH[yRZBUSU6JRWK=
NCI-H719	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTBwMEe4PFgh\|ryP	MVvTRW5ITVJ?
MLMA	M4qw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\F[FJKSzVyPUCuNFkxPiEQvF2=	NWnmRZFVW0GQR1XS
KM12	Mk\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\SSYlKSzVyPUCuNFk4OzdizszN	MULTRW5ITVJ?
SUP-T1	NHPIWJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DudGlEPTB;MD6wPVk5OiEQvF2=	MYPTRW5ITVJ?
MZ1-PC	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTBwMUGzN\|Yh\|ryP	M13k[XNCVkeHUh?=
MFE-296	M4\QfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4OwSWlEPTB;MD6xNVg{QSEQvF2=	Mke5V2FPT0WU
ALL-PO	MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7XTWM2OD1yLkGyOFQ{KM7:TR?=	MWDTRW5ITVJ?
GB-1	M2rmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2exTGlEPTB;MD6xNlUyOiEQvF2=	MUDTRW5ITVJ?
SIG-M5	MlTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTBwMUOzO{DPxE1?	M3nvdHNCVkeHUh?=
P30-OHK	M3zKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7YR4RmUUN3ME2wMlE2Pjd{IN88US=>	NHLIbIhUSU6JRWK=
NCI-H716	M4LDT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\wZ\|ZUUUN3ME2wMlE3OjZ4IN88US=>	M4j5V3NCVkeHUh?=
MPP-89	NF3KS3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkX2TWM2OD1yLkG2PVM{KM7:TR?=	MkXMV2FPT0WU
SF126	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1y0eGlEPTB;MD6xO\|A3OyEQvF2=	Mlv5V2FPT0WU
CTB-1	NWLDVJpOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV7JR\|UxRTBwMUezNVYh\|ryP	M4rEXHNCVkeHUh?=
CA46	NYHvVotJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\GTWM2OD1yLkG3OFg6KM7:TR?=	M2f0d3NCVkeHUh?=
NCI-H520	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHz5d3FKSzVyPUCuNVc4OzJizszN	NXXJS3hPW0GQR1XS
CAL-85-1	M1u0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlmwTWM2OD1yLkG3PVI4KM7:TR?=	M{TmVXNCVkeHUh?=
NCI-H2342	M3P4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LDRWlEPTB;MD6xPFU4PyEQvF2=	NGGybZFUSU6JRWK=
697	NXfOTnVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLRTWM2OD1yLkG4PFcyKM7:TR?=	NHTmcFNUSU6JRWK=
NY	MoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHRdHloUUN3ME2wMlE6Ojh5IN88US=>	M2L4UXNCVkeHUh?=
T98G	NIfoN3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2KzdGlEPTB;MD6xPVMyQCEQvF2=	NHX3V4tUSU6JRWK=
NCI-H1703	NHvsV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFP6[4pKSzVyPUCuNVk3OTVizszN	NVjZVYQ5W0GQR1XS
NCI-H2087	NEnodXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\hTWM2OD1yLkKwOFM6KM7:TR?=	MXvTRW5ITVJ?
PF-382	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY[4NJhRUUN3ME2wMlIxQDd\|IN88US=>	MkXCV2FPT0WU
HCT-116	MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\tU2lEPTB;MD6yNVA3QSEQvF2=	NWjCfJdlW0GQR1XS
CAKI-1	MkDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFK2[m5KSzVyPUCuNlE3PjZizszN	MkfyV2FPT0WU
CCF-STTG1	MnK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\sNmQzUUN3ME2wMlIzPDd3IN88US=>	NGfmZ2xUSU6JRWK=
D-392MG	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3WTIZWUUN3ME2wMlI{OTd5IN88US=>	MW\TRW5ITVJ?
RT-112	M4TBUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXkTWM2OD1yLkKzO\|k2KM7:TR?=	NVTHWm04W0GQR1XS
MES-SA	M3G5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTBwMkSxPFch\|ryP	M1zsTnNCVkeHUh?=
LC-2-ad	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF7YW2lKSzVyPUCuNlQzPjVizszN	MYrTRW5ITVJ?
NOS-1	MlH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzCTWM2OD1yLkK0N\|Y4KM7:TR?=	MnXDV2FPT0WU
NALM-6	MkPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEC4UJJKSzVyPUCuNlU2PDNizszN	MVHTRW5ITVJ?
TE-15	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\aTWM2OD1yLkK2NFkyKM7:TR?=	M1zrOXNCVkeHUh?=
786-0	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFX6UYVKSzVyPUCuNlYzOjhizszN	MYDTRW5ITVJ?
IST-MES1	NF;2OItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLSUYFKSzVyPUCuNlY5OjlizszN	NH\1fZFUSU6JRWK=
KYSE-180	M{PWWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknxTWM2OD1yLkK2PFkyKM7:TR?=	NWXkZpZVW0GQR1XS
YT	MnHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXRTWM2OD1yLkK2PVc1KM7:TR?=	M{D1RnNCVkeHUh?=
A427	NES1c5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3r3e2lEPTB;MD6yO\|I3PCEQvF2=	MUXTRW5ITVJ?
KYSE-450	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zYXWlEPTB;MD6yO\|MzQSEQvF2=	MkjuV2FPT0WU
HuH-7	M4LRUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\MeHRXUUN3ME2wMlI4PzZ\|IN88US=>	NIrQcZhUSU6JRWK=
CAS-1	Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrIOXVKSzVyPUCuNlg{ODNizszN	NF36TlJUSU6JRWK=
KURAMOCHI	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfSdoVKSzVyPUCuNlg1OTlizszN	M2LMW3NCVkeHUh?=
ACHN	M3vBVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;TOpNKSzVyPUCuNlk{OjNizszN	NEfXXGFUSU6JRWK=
HGC-27	Mn\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXr3VZFMUUN3ME2wMlI6OzV\|IN88US=>	NWHR[HE2W0GQR1XS
A172	M1SzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmO5TWM2OD1yLkK5OVc4KM7:TR?=	MX;TRW5ITVJ?
SNU-449	MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTBwMkm5OlQh\|ryP	NXv6Rms{W0GQR1XS
SW982	MofpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlr1TWM2OD1yLkK5PVc5KM7:TR?=	NUTUfZkyW0GQR1XS
EFO-21	M{fKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEm5V5FKSzVyPUCuN\|A1OTFizszN	MofVV2FPT0WU
NCI-H2030	NFPTfnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTBwM{GxOlQh\|ryP	MkDHV2FPT0WU
HT-144	NYDMTFJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HoXGlEPTB;MD6zNVI5KM7:TR?=	Mn7nV2FPT0WU
MFE-280	MoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwM{G0OVMh\|ryP	NVfxUJZ1W0GQR1XS
SK-LU-1	NFzKWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTBwM{G0OlYh\|ryP	NGCyfm1USU6JRWK=
NCI-H2052	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETHcVBKSzVyPUCuN\|E1QDRizszN	M323TXNCVkeHUh?=
SK-HEP-1	MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\FTWM2OD1yLkOzN\|Y5KM7:TR?=	MXPTRW5ITVJ?
QIMR-WIL	NXfQZm4zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTBwM{O0NlQh\|ryP	NGPxfFdUSU6JRWK=
A2780	M1SxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rremlEPTB;MD6zOFMxPCEQvF2=	NYH4eY5OW0GQR1XS
ACN	NYSwfVduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTBwM{S4O\|Mh\|ryP	NX[1bllmW0GQR1XS
BxPC-3	Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHe1enZKSzVyPUCuN\|Q6QDlizszN	MV3TRW5ITVJ?
BCPAP	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnyZpRpUUN3ME2wMlM3ODBzIN88US=>	MmXsV2FPT0WU
HOP-62	M3SxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;lTWM2OD1yLkO2NVA3KM7:TR?=	NIrSenhUSU6JRWK=
SW1710	NFjnTY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13hN2lEPTB;MD6zOlQ2PSEQvF2=	MX7TRW5ITVJ?
OPM-2	NUG3OW1FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrCO5ZKSzVyPUCuN\|Y1PzNizszN	Mn\LV2FPT0WU
DBTRG-05MG	NELab4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTBwM{iwOVQh\|ryP	NWnWXnVmW0GQR1XS
SK-MEL-24	NYrTZ3ZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7IR4hYUUN3ME2wMlM6PzlzIN88US=>	M{nMdnNCVkeHUh?=
8305C	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vDTGlEPTB;MD6zPVc6OyEQvF2=	NYPFdG93W0GQR1XS
OVCAR-4	M3TQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPMfnlPUUN3ME2wMlQyPTh4IN88US=>	MXjTRW5ITVJ?
HLE	M2PDNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnR[ZJKUUN3ME2wMlQyQDZizszN	M{f5enNCVkeHUh?=
NCI-H747	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfTUJNuUUN3ME2wMlQzOTN5IN88US=>	NWjlfYN3W0GQR1XS
SW780	NGDpT4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PFWmlEPTB;MD60NlM1PiEQvF2=	NHXRSlNUSU6JRWK=
KYSE-150	Mli4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTBwNEK0NVUh\|ryP	MWLTRW5ITVJ?
H4	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTOTWM2OD1yLkSyOFUyKM7:TR?=	MX;TRW5ITVJ?
SW1088	NIP3fW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTBwNESzPUDPxE1?	NUD4eY5xW0GQR1XS
SF268	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHSPHZ4UUN3ME2wMlQ1QDZizszN	NEPkTGFUSU6JRWK=
RT4	NYP4cmlbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTBwNEWxNVEh\|ryP	NIW4XZVUSU6JRWK=
NCI-H522	MmnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPPbW5KSzVyPUCuOFUzPyEQvF2=	MmT6V2FPT0WU
LCLC-97TM1	NGjZT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3m5eGlEPTB;MD60OlE6PSEQvF2=	NG\FTZpUSU6JRWK=
CAL-39	MknZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTBwNE[1NVkh\|ryP	Mo\PV2FPT0WU
CAL-120	NVu4fpU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jTW2lEPTB;MD60O\|Y1OyEQvF2=	NXT3[HdjW0GQR1XS
ESS-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PtXmlEPTB;MD60O\|gzOSEQvF2=	NIrqNJRUSU6JRWK=
KARPAS-45	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3IN2hKSzVyPUCuOFg6OzNizszN	MYjTRW5ITVJ?
DU-4475	NXHpTXJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLwXnRKSzVyPUCuOFk2OTFizszN	NH;lT\|ZUSU6JRWK=
VMRC-RCZ	MoG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PQeWlEPTB;MD60PVkxPCEQvF2=	M{LodHNCVkeHUh?=
HOS	MnHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M36zVWlEPTB;MD61NFM3PSEQvF2=	NW\sdpV3W0GQR1XS
MOLT-16	MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLwPHFKSzVyPUCuOVE5ODhizszN	M3Tkd3NCVkeHUh?=
RPMI-6666	M{nkOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13yVWlEPTB;MD61NlE{PSEQvF2=	M4H1enNCVkeHUh?=
K052	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlr3TWM2OD1yLkWyNVQh\|ryP	NHLrOIFUSU6JRWK=
EHEB	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTBwNUKxPFIh\|ryP	NFnF[VlUSU6JRWK=
MFH-ino	M{HDNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\UfVZKSzVyPUCuOVI{PTFizszN	NWnTXZJjW0GQR1XS
A4-Fuk	M1TVPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\OS\|hKSzVyPUCuOVI2OjhizszN	M2HNR3NCVkeHUh?=
SW1417	MnrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjwZXBKSzVyPUCuOVI4QDFizszN	Mk[zV2FPT0WU
DoTc2-4510	NHzGOYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHKTWM2OD1yLkW0PVU5KM7:TR?=	NX;2R\|RtW0GQR1XS
TE-12	NHHGeXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHNNJJqUUN3ME2wMlU2PzN3IN88US=>	MVTTRW5ITVJ?
8-MG-BA	NXfMZVZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnKR4JKSzVyPUCuOVYxPTZizszN	MUXTRW5ITVJ?
ECC12	M{XhfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPwXIZKSzVyPUCuOVY2PThizszN	NUSxO3VwW0GQR1XS
CHL-1	NHXTU45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4iyPGlEPTB;MD61O\|Q3OyEQvF2=	MYjTRW5ITVJ?
LCLC-103H	NH;JcohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LLXWlEPTB;MD61PFM1PCEQvF2=	NVviXY86W0GQR1XS
OS-RC-2	NIniXFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLkTWM2OD1yLkW4N\|c6KM7:TR?=	NIHnPG1USU6JRWK=
RO82-W-1	M37rU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2Tnd2lEPTB;MD61PVYyPSEQvF2=	NXL0b5lNW0GQR1XS
A3-KAW	NWW1W5g2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTBwNkG0Olch\|ryP	NYDIZWJIW0GQR1XS
NCCIT	NWXwXo94T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XWTmlEPTB;MD62NVcyPSEQvF2=	MWjTRW5ITVJ?
IST-SL2	M{nJ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTBwNkK1NlIh\|ryP	NGLrcmhUSU6JRWK=
GI-ME-N	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLFO49RUUN3ME2wMlY{ODZ7IN88US=>	M1jpN3NCVkeHUh?=
ES6	MoPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTBwNkOyPVUh\|ryP	MWfTRW5ITVJ?
BL-41	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\WSm1KSzVyPUCuOlM{PTJizszN	MXjTRW5ITVJ?
Ca-Ski	M3rnOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PZS2lEPTB;MD62OFgyKM7:TR?=	MWHTRW5ITVJ?
HOP-92	M3K0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTPTWM2OD1yLk[1OlczKM7:TR?=	NV7oUmdHW0GQR1XS
SK-LMS-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVn3e4pzUUN3ME2wMlY3PDdizszN	NVLwfIpCW0GQR1XS
EW-13	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX3Fb2JDUUN3ME2wMlY3Pzd7IN88US=>	M3Xk[XNCVkeHUh?=
647-V	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;nZXQ3UUN3ME2wMlY5OTR6IN88US=>	Mm\WV2FPT0WU
JiyoyeP-2003	Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoezTWM2OD1yLk[5O\|M5KM7:TR?=	NFvGbnpUSU6JRWK=
WSU-NHL	NUT3cHUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfBbnZDUUN3ME2wMlcxQDh5IN88US=>	MXzTRW5ITVJ?
U-698-M	NVOzSIRoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\3TWM2OD1yLkexNFY{KM7:TR?=	NVe3WFBKW0GQR1XS
HC-1	NUXvSY0zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7mTWM2OD1yLkeyOFA2KM7:TR?=	MWXTRW5ITVJ?
8505C	MnToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLxTWM2OD1yLkeyO\|QyKM7:TR?=	MWLTRW5ITVJ?
HUTU-80	M1nu[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HU[WlEPTB;MD63N\|M1QSEQvF2=	MXXTRW5ITVJ?
LB1047-RCC	Ml;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXWxTHNGUUN3ME2wMlc{PTN6IN88US=>	NHzJdINUSU6JRWK=
GAMG	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXv4VYIzUUN3ME2wMlc{PjV\|IN88US=>	MUHTRW5ITVJ?
CAL-12T	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DiXmlEPTB;MD63N\|g4PyEQvF2=	M{L0NXNCVkeHUh?=
NCI-SNU-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTy[3BvUUN3ME2wMlc4Ojd6IN88US=>	NWTWOpRPW0GQR1XS
HTC-C3	M3jLRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PqVGlEPTB;MD63O\|Q2OSEQvF2=	MlfMV2FPT0WU
HPAF-II	MkSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzXepJKSzVyPUCuO\|c2ODFizszN	MlO0V2FPT0WU
KGN	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXGXGFKSzVyPUCuO\|gxQDFizszN	NWnuOVcxW0GQR1XS
EFO-27	MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDJbIt5UUN3ME2wMlc5PzN\|IN88US=>	NIPOWIdUSU6JRWK=
MEL-HO	NHLzSpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTBwN{m0OFkh\|ryP	NXnvUGZmW0GQR1XS
KYSE-270	MkfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH:3VY9KSzVyPUCuPFA2OjlizszN	NE\GSWNUSU6JRWK=
NCI-H1755	NUXX[oROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTBwOEC3NVQh\|ryP	M32yU3NCVkeHUh?=
MFM-223	M321NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUH3bZp1UUN3ME2wMlgyPDB5IN88US=>	MV7TRW5ITVJ?
G-361	MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTBwOEG4PVch\|ryP	NU\lZ\|JMW0GQR1XS
ETK-1	NET6N5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\ac\|VKSzVyPUCuPFI1PDFizszN	MVLTRW5ITVJ?
LU-99A	NE\JXYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTBwOES3NFEh\|ryP	MlnIV2FPT0WU
IST-MEL1	MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPud2hKSzVyPUCuPFU4OzJizszN	NWjjUIxSW0GQR1XS
L-540	NGr5NVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDQTWM2OD1yLki1PFAyKM7:TR?=	NGrjVI5USU6JRWK=
U-2-OS	M1r0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTnbItuUUN3ME2wMlg2QDR4IN88US=>	MUDTRW5ITVJ?
HT-1376	M2r3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4qxWWlEPTB;MD64OlA2OSEQvF2=	NEDrbm9USU6JRWK=
COLO-680N	NFHOXZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDpTWM2OD1yLki3PVM{KM7:TR?=	NFnyW4VUSU6JRWK=
NCI-H1581	MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWO0fnNUUUN3ME2wMlg6Ojl5IN88US=>	MYHTRW5ITVJ?
HuCCT1	NXLldXVTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYLWU\|hbUUN3ME2wMlg6PTR6IN88US=>	MlXtV2FPT0WU
BB30-HNC	NUC3clRUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M122bGlEPTB;MD65NlQ3QSEQvF2=	M{e2fHNCVkeHUh?=
NCI-H2347	M4naPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2Xp[WlEPTB;MD65N\|I6OiEQvF2=	M{PIeXNCVkeHUh?=
G-401	MnHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTBwOUO2PVUh\|ryP	NF62WVRUSU6JRWK=
NCI-H358	MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fHbmlEPTB;MD65OVAyPCEQvF2=	NXrOfYtyW0GQR1XS
HCC1395	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\jOGpWUUN3ME2wMlk2PDZzIN88US=>	M3SxbnNCVkeHUh?=
J82	NIHS[ZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fEN2lEPTB;MD65OVU1OyEQvF2=	MoLBV2FPT0WU
KE-37	M3H2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwOU[zPFch\|ryP	MXnTRW5ITVJ?
NOMO-1	MkfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTBwOU[1OlQh\|ryP	MX3TRW5ITVJ?
ML-2	M1TnSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTBwOUm3OUDPxE1?	NFG2UWtUSU6JRWK=
SW872	M{Kyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTBwOUm3O\|Uh\|ryP	NEHzUmVUSU6JRWK=
KYSE-520	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLEc41iUUN3ME2xMlAxPDl2IN88US=>	NIm4RnhUSU6JRWK=
HL-60	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjycI1KSzVyPUGuNFA6PyEQvF2=	NFLNWo9USU6JRWK=
HDLM-2	Mn7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTFwMEGyOVIh\|ryP	M3H6dHNCVkeHUh?=
MIA-PaCa-2	NWrlfIs4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHXSWFKSzVyPUGuNFE{PzVizszN	M4rM[XNCVkeHUh?=
TCCSUP	MnvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fkSWlEPTB;MT6wNVc{OiEQvF2=	NYHRTYo4W0GQR1XS
SH-4	NVTBR2hsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYLrNppmUUN3ME2xMlAzOjR2IN88US=>	NXn3VY1rW0GQR1XS
MG-63	Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDITWM2OD1zLkCyOlE3KM7:TR?=	MnXNV2FPT0WU
NB6	M3\3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGrkXndKSzVyPUGuNFMyODlizszN	NYPzUVd1W0GQR1XS
CAL-54	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnrRnNkUUN3ME2xMlA{QTV7IN88US=>	Mmr0V2FPT0WU
DU-145	MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTFwMEiwO\|Mh\|ryP	M3PTUHNCVkeHUh?=
HCE-4	NH7wOnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HtN2lEPTB;MT6wPVI5PiEQvF2=	M1nkNXNCVkeHUh?=
U-266	NWHkb2VnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTFwMEm2N\|Mh\|ryP	NFz0SWlUSU6JRWK=
HT-1197	MnrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPXW3d5UUN3ME2xMlEyPDN6IN88US=>	MVvTRW5ITVJ?
EW-1	NVvZbWpoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTFwMUSxNlgh\|ryP	NFXseY5USU6JRWK=
MHH-NB-11	MnHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\4VmJKSzVyPUGuNVU{PjhizszN	NWiy[ZNjW0GQR1XS
NCI-H2405	NXfhWZFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVf4NoN4UUN3ME2xMlE3OTZizszN	NVTRUmhoW0GQR1XS
COLO-668	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTFwMU[0PUDPxE1?	MULTRW5ITVJ?
IMR-5	NY[2bIp[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfYS3p2UUN3ME2xMlE3QTN4IN88US=>	MVXTRW5ITVJ?
ARH-77	NFzmc5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorKTWM2OD1zLkKyPVI1KM7:TR?=	M2[zdXNCVkeHUh?=
BHT-101	NILY[2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zZNGlEPTB;MT6yN\|Q6KM7:TR?=	NEHTcVlUSU6JRWK=
SCC-25	NGfm[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;rTWM2OD1zLkKzOVM3KM7:TR?=	MkD0V2FPT0WU
NTERA-S-cl-D1	NGjBPXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTFwMkSzOFYh\|ryP	M2fPSHNCVkeHUh?=
MKN28	M{H5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3VS\|RMUUN3ME2xMlI2PjN4IN88US=>	MX7TRW5ITVJ?
KS-1	NUnrXJVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3qx[2lEPTB;MT6yPFI3QSEQvF2=	NUjHU4ROW0GQR1XS
NCI-H1734	NXv1XooxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIixNVdKSzVyPUGuNlg6OTNizszN	Mmr5V2FPT0WU
ES7	M2O1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjNXI1KSzVyPUGuNlk2PDJizszN	MoXkV2FPT0WU
NCI-H838	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\vdWlEPTB;MT6zNFYyPSEQvF2=	NV\rXZlYW0GQR1XS
HEC-1	M{XMOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjzSIVKSzVyPUGuN\|M4PTVizszN	NUTpTZF7W0GQR1XS
ME-180	NYna[YU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXqOo9pUUN3ME2xMlM4QTl\|IN88US=>	NIrqb2RUSU6JRWK=
MMAC-SF	MlmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MknFTWM2OD1zLkO5OVk2KM7:TR?=	MoXsV2FPT0WU
IA-LM	NGi4NHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYiyS4lGUUN3ME2xMlQxQTF2IN88US=>	NVjuZ5FwW0GQR1XS
MN-60	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfBTWM2OD1zLkSzNVE1KM7:TR?=	NGL6dXFUSU6JRWK=
SIMA	M{Pjbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTFwNEi2PFch\|ryP	MWXTRW5ITVJ?
NCI-H1770	M3jMVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTFwNUKwOVQh\|ryP	NV:2enBKW0GQR1XS
ONS-76	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDFTWM2OD1zLkWyN\|EyKM7:TR?=	NV3jRnl4W0GQR1XS
LB771-HNC	MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13Yd2lEPTB;MT61N\|kxPiEQvF2=	M33JXXNCVkeHUh?=
SW48	NXfYUJRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTFwNUSyOFMh\|ryP	NE\ZeYRUSU6JRWK=
KYSE-140	NGDwXpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXhTWM2OD1zLkW1O\|QyKM7:TR?=	M2PiPHNCVkeHUh?=
SW626	NVXMcXpLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jnemlEPTB;MT61PFE3KM7:TR?=	MnLNV2FPT0WU
MC-CAR	NYfMcGpjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonRTWM2OD1zLkW4OlY{KM7:TR?=	MXHTRW5ITVJ?
D-336MG	M{LHd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI[yWZBKSzVyPUGuOlI6PCEQvF2=	MYDTRW5ITVJ?
SK-MEL-3	NXrPZVlIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHJdnFMUUN3ME2xMlY{QTB{IN88US=>	MXLTRW5ITVJ?
MHH-PREB-1	NFLBOJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmr4TWM2OD1zLk[0OFc{KM7:TR?=	MnnYV2FPT0WU
Calu-1	NHfrcGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYj0ZYtDUUN3ME2xMlY2Ozh4IN88US=>	MUTTRW5ITVJ?
HCC1806	NFrKdFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\BbVFJUUN3ME2xMlY3PjFzIN88US=>	NX;qfGtzW0GQR1XS
A101D	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTFwNk[3PFEh\|ryP	NEXKOmlUSU6JRWK=
A704	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPXbo41UUN3ME2xMlY5OzFzIN88US=>	NIjtbIFUSU6JRWK=
LB831-BLC	NUDrVmQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTFwNkm4OVQh\|ryP	MWXTRW5ITVJ?
RL95-2	Mof1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzUNmVKSzVyPUGuO\|E1PjNizszN	MXrTRW5ITVJ?
RPMI-2650	M1\VT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXMTWM2OD1zLkeyO\|E6KM7:TR?=	M3fBWnNCVkeHUh?=
NH-12	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTHXFZuUUN3ME2xMlc{PDJ5IN88US=>	NIC5bFZUSU6JRWK=
AGS	MoDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLLSXh6UUN3ME2xMlc3OzV6IN88US=>	NVKxOGZLW0GQR1XS
NEC8	MoLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTFwN{i5PVUh\|ryP	NXKyb4Z{W0GQR1XS
NCI-H2009	NIHoS5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XWemlEPTB;MT63PVczOSEQvF2=	M2K1NHNCVkeHUh?=
A498	M164TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPHTWM2OD1zLkixNlgzKM7:TR?=	NGP3e3dUSU6JRWK=
NCI-H810	M3iz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTFwOEG2NFYh\|ryP	NFfvUWRUSU6JRWK=
SK-NEP-1	M1;i[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mme2TWM2OD1zLkizO\|Y4KM7:TR?=	NYHvbWJTW0GQR1XS
D-542MG	NHrkdHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7XeWFKSzVyPUGuPFU5PTFizszN	M2TRNXNCVkeHUh?=
KNS-42	NVr1WotUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPnNYd1UUN3ME2xMlg3OjZ4IN88US=>	MXjTRW5ITVJ?
NCI-H2452	MnfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\6fFlKSzVyPUGuPFkxPzRizszN	NHHqbpZUSU6JRWK=
SK-MEL-2	Mo\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3w[VJOUUN3ME2xMlkxOjdzIN88US=>	NY\KSYZ{W0GQR1XS
OVCAR-5	NXXNWphmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPSTWM2OD1zLkmwOlc2KM7:TR?=	MWLTRW5ITVJ?
SNG-M	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXFXGxKSzVyPUGuPVU5PThizszN	NFzJVmpUSU6JRWK=
A673	NXHFPIZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4D4Z2lEPTB;MT65O\|UyPiEQvF2=	NF7BVWhUSU6JRWK=
L-428	NVjlelZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmn0TWM2OD1zLkm5NVc6KM7:TR?=	NGqwUFRUSU6JRWK=
KM-H2	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\lblljUUN3ME2yMlAyODlizszN	NVfIbVI6W0GQR1XS
MC-IXC	M13ob2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTJwMEKyO\|Mh\|ryP	NYPrd\|dlW0GQR1XS
COLO-678	Mkf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTJwMESyNFch\|ryP	Mn7rV2FPT0WU
MEL-JUSO	MnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHSR2NZUUN3ME2yMlA4QDVzIN88US=>	NWLaUJJYW0GQR1XS
HCC38	MmntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlG0TWM2OD1{LkC4OFM{KM7:TR?=	M2fsWXNCVkeHUh?=
UACC-62	NELH[o9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mkj3TWM2OD1{LkC4PFU2KM7:TR?=	MYHTRW5ITVJ?
OAW-42	NUC1eVZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7z[lRKSzVyPUKuNFk4OTFizszN	MXfTRW5ITVJ?
LB996-RCC	NIf1[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HxbmlEPTB;Mj6xN\|gyPyEQvF2=	NHLMNXpUSU6JRWK=
COR-L105	M{ezXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPyZVd6UUN3ME2yMlE3Ozd\|IN88US=>	NG\qN\|FUSU6JRWK=
RCC10RGB	M1jXTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTJwMUi1O\|Yh\|ryP	MYfTRW5ITVJ?
A431	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnNTWM2OD1{LkG5NFE6KM7:TR?=	Mn3XV2FPT0WU
NCI-H292	MoXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2L3e2lEPTB;Mj6yN\|k2OSEQvF2=	Mm\PV2FPT0WU
SK-UT-1	NGeyRXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LRfmlEPTB;Mj6zN\|E5PCEQvF2=	M4PWTXNCVkeHUh?=
PANC-08-13	NELXWFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTJwM{OyN\|Uh\|ryP	MULTRW5ITVJ?
ST486	MkXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PGU2lEPTB;Mj60NVA1QCEQvF2=	MYnTRW5ITVJ?
SJSA-1	M3zFT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnDTWM2OD1{LkSxNlcyKM7:TR?=	NXfLT2pUW0GQR1XS
RKO	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTJwNEKwNlkh\|ryP	MkPzV2FPT0WU
NCI-H1793	Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorFTWM2OD1{LkS0NFI6KM7:TR?=	NXT4XXlFW0GQR1XS
639-V	NHS5TXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTJwNEWzPFIh\|ryP	Mn62V2FPT0WU
ES3	MknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfaUYVKSzVyPUKuOFk4OzdizszN	M2f2PHNCVkeHUh?=
NCI-H1792	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDZR5RKSzVyPUKuOVY5OjZizszN	MWnTRW5ITVJ?
NCI-H1651	M4X1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HzSWlEPTB;Mj61PFIyKM7:TR?=	NIW1NW9USU6JRWK=
SN12C	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXhTWM2OD1{LkW4OFg4KM7:TR?=	M{HNfHNCVkeHUh?=
COLO-679	MlTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUC4dGxsUUN3ME2yMlU5PjB3IN88US=>	M2D5cXNCVkeHUh?=
U-118-MG	NInVWpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3q2[GlEPTB;Mj61PFg4OiEQvF2=	NF30cWFUSU6JRWK=
Ramos-2G6-4C10	M3fqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7j[HFKSzVyPUKuOlQ5ODdizszN	MkP5V2FPT0WU
HCT-15	NUC0cmpPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHsPHhKSzVyPUKuOlg4QTJizszN	M3XLWnNCVkeHUh?=
MDA-MB-157	NFrFUXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLSTWM2OD1{LkewO\|Q4KM7:TR?=	M{e4bXNCVkeHUh?=
K5	NXj2PIw5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfwTWM2OD1{LkexPFQ2KM7:TR?=	NGfIcWJUSU6JRWK=
MKN45	NXHwTnd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3TVYNYUUN3ME2yMlc{OzZ4IN88US=>	NFj2SXhUSU6JRWK=
DMS-273	NUPvXWdnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTJwN{W2N\|Ih\|ryP	NH\VUoJUSU6JRWK=
C8166	M3ThZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLxXIxyUUN3ME2yMlc5PTF\|IN88US=>	NHvkPFZUSU6JRWK=
Calu-3	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrsUnhoUUN3ME2yMlc5QTZ7IN88US=>	M2nDVXNCVkeHUh?=
SNB75	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDDTWM2OD1{Lki4OVM2KM7:TR?=	NHG2S5ZUSU6JRWK=
BFTC-905	NFG3[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2C0dmlEPTB;Mj65NFE6OSEQvF2=	NHz6dIVUSU6JRWK=
C-4-II	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTJwOUGzOVMh\|ryP	M2jOdXNCVkeHUh?=
MS-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4Xh[GlEPTB;Mj65Olc3QSEQvF2=	M1[x[3NCVkeHUh?=
A375	MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvKXVJWUUN3ME2zMlA5OTh2IN88US=>	M2DrWXNCVkeHUh?=
KYSE-70	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTNwMEi4PFIh\|ryP	M3;JNHNCVkeHUh?=
KYSE-510	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTEN5RqUUN3ME2zMlExQTl3IN88US=>	M2LNUnNCVkeHUh?=
LN-405	NXnWc5lsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTNwMUO1NVgh\|ryP	NUnqdJE1W0GQR1XS
BOKU	MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnTcGVoUUN3ME2zMlE1OjV4IN88US=>	MU\TRW5ITVJ?
TE-10	M1\Ee2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX[1b\|V2UUN3ME2zMlE4OzZ{IN88US=>	NG\LUolUSU6JRWK=
MKN1	NXnKTW4{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\wVIVKSzVyPUOuNVg1QDNizszN	NVvMUWZ2W0GQR1XS
M059J	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLod3RnUUN3ME2zMlIxOTd\|IN88US=>	NXLhe5YzW0GQR1XS
GOTO	NEjQR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LCUWlEPTB;Mz6yNlA{QSEQvF2=	NGe5TWVUSU6JRWK=
DK-MG	M4f4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTRbnJKSzVyPUOuNlU6PzZizszN	NETsWWtUSU6JRWK=
NCI-H727	NF22b3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWL2PIJ4UUN3ME2zMlI3PThizszN	M{WxOXNCVkeHUh?=
NB12	NEDZenhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTNwM{OyNlQh\|ryP	MWXTRW5ITVJ?
DOK	NFnqdG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTNwM{[xPFYh\|ryP	M4DzW3NCVkeHUh?=
KYSE-410	NHPtXpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7ETWM2OD1\|LkO2Nlg4KM7:TR?=	NGnoPZFUSU6JRWK=
AM-38	NV;CUohrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfrUVhKSzVyPUOuN\|gxPTFizszN	MWTTRW5ITVJ?
GR-ST	M1vSfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnFOYdKSzVyPUOuOFU4OzJizszN	NEXubVhUSU6JRWK=
D-247MG	NIHnVHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3BXJBKSzVyPUOuOFgzPjNizszN	MmK3V2FPT0WU
TE-8	NEL0VZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTjTWM2OD1\|LkS5N\|M{KM7:TR?=	M1LHSXNCVkeHUh?=
LS-411N	MkLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfKe5lHUUN3ME2zMlQ6Pjl{IN88US=>	M1;1R3NCVkeHUh?=
SK-MES-1	NE\uPW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1SzTGlEPTB;Mz61OlQ{OyEQvF2=	MWLTRW5ITVJ?
SF295	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TqNWlEPTB;Mz62NVU2OiEQvF2=	MWPTRW5ITVJ?
SK-MEL-30	NG\0U2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;VcWwxUUN3ME2zMlY2QTJzIN88US=>	MnewV2FPT0WU
LB2241-RCC	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDoU\|NKSzVyPUOuOlYzPiEQvF2=	NWnmNnZbW0GQR1XS
PC-14	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7Kd\|J6UUN3ME2zMlY3PDN5IN88US=>	MlzzV2FPT0WU
EW-7	Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\MTWM2OD1\|Lk[3Olk{KM7:TR?=	MX\TRW5ITVJ?
NMC-G1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX3mdYJ{UUN3ME2zMlcyQDN5IN88US=>	MofRV2FPT0WU
TE-441-T	NYX6ZYV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPXVXliUUN3ME2zMlc{ODJ6IN88US=>	M1fOe3NCVkeHUh?=
NCI-H1618	Mm\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DBcWlEPTB;Mz64NVg4PSEQvF2=	NXTsXphjW0GQR1XS
PANC-03-27	MnXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PZUGlEPTB;Mz64NVkyPiEQvF2=	NXj6VmtRW0GQR1XS
NCI-H2228	NX\qN4NPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWeyVVFZUUN3ME2zMlg{OTJ4IN88US=>	NFnZbYxUSU6JRWK=
CAPAN-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{K0bmlEPTB;Mz64O\|AxQSEQvF2=	NVn4Nm13W0GQR1XS
KLE	M{\HSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPzdFVKSzVyPUOuPVA3PyEQvF2=	MXnTRW5ITVJ?
Becker	NX;0eoU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPnc2JKSzVyPUOuPVI5PDlizszN	MWrTRW5ITVJ?
SK-PN-DW	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzuUm5KSzVyPUSuNFc6PzRizszN	MkX2V2FPT0WU
Hs-578-T	MlyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\Fd\|BNUUN3ME20MlA5OzB4IN88US=>	MXTTRW5ITVJ?
RS4-11	NHzwVHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7ETWM2OD12LkGxNlU2KM7:TR?=	NUflOY1kW0GQR1XS
D-502MG	NVrLSmd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\Jd3hKSzVyPUSuNVY6QTdizszN	MVzTRW5ITVJ?
GI-1	M2DrdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPjO3VKSzVyPUSuNlgzQTlizszN	MlfiV2FPT0WU
NCI-H209	M4G2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXxTJJKSzVyPUSuN\|M4QCEQvF2=	M2rJR3NCVkeHUh?=
SK-OV-3	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\vV4twUUN3ME20MlQ5OTR7IN88US=>	MV\TRW5ITVJ?
LOUCY	MkfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTRwNEi0N\|Ih\|ryP	MoDXV2FPT0WU
NCI-H69	Mo\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTRwNUG3PVMh\|ryP	M1;LS3NCVkeHUh?=
SCC-9	MlOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LFfWlEPTB;ND61N\|E4OiEQvF2=	M1rOfHNCVkeHUh?=
NCI-H526	NELr[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELNXnJKSzVyPUSuOVkzQTNizszN	NILRRmZUSU6JRWK=
NCI-H2170	NVTtb5NnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\M[JZKSzVyPUSuOlY4PzFizszN	NE[2S5hUSU6JRWK=
SR	NGq1ZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mly0TWM2OD12LkewNFQ5KM7:TR?=	NHLqeFRUSU6JRWK=
CMK	MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXsTWM2OD12LkeyNVAyKM7:TR?=	NFfYTpdUSU6JRWK=
COLO-829	M4njOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTRwN{ewOFMh\|ryP	MVfTRW5ITVJ?
HuO-3N1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LDO2lEPTB;ND64N\|I5OSEQvF2=	NHS4cpBUSU6JRWK=
5637	MofGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;TN2lEPTB;ND65NFQ5PyEQvF2=	M333ZXNCVkeHUh?=
A253	M4nDeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfrc\|ZxUUN3ME20Mlk4PzB6IN88US=>	Mlv2V2FPT0WU
NB10	Mmf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nKXmlEPTB;NT6wO\|Q6PyEQvF2=	MUTTRW5ITVJ?
SF539	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoL3TWM2OD13LkC5PVU6KM7:TR?=	NXzDW\|E2W0GQR1XS
HAL-01	NW\XR3U6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vOU2lEPTB;NT6xOFY1PSEQvF2=	NHS5XFZUSU6JRWK=
MHH-ES-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PDdWlEPTB;NT6xOlkzPSEQvF2=	NX;IcWN4W0GQR1XS
DEL	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXj3[YNWUUN3ME21MlI4PTh{IN88US=>	M1:zO3NCVkeHUh?=
NCI-H1299	NF3XTphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVT6co9lUUN3ME21MlM2ODB5IN88US=>	NI\2XlRUSU6JRWK=
ChaGo-K-1	NE[wNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rUdmlEPTB;NT6zOVExPyEQvF2=	M1LMXXNCVkeHUh?=
HMV-II	NX;USZhyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fDRWlEPTB;NT6zPVQ{KM7:TR?=	MlXqV2FPT0WU
NB69	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnP[VFKSzVyPUWuN\|k3OzFizszN	MYrTRW5ITVJ?
NCI-H1882	NVLoVHVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmThTWM2OD13LkSzN\|Y1KM7:TR?=	MXLTRW5ITVJ?
SNU-475	NEOwSnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jPUGlEPTB;NT60O\|E4OSEQvF2=	M2PmRXNCVkeHUh?=
RXF393	M3\ZR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rRN2lEPTB;NT60PFQ6PCEQvF2=	MmK1V2FPT0WU
CAL-51	NYHqcXRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTVwNkK4OVMh\|ryP	MWLTRW5ITVJ?
SW1573	MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{mxR2lEPTB;NT62N\|U{PCEQvF2=	MnPKV2FPT0WU
GCT	M2DQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTVwN{W5Nlkh\|ryP	NXvMRWV5W0GQR1XS
COR-L88	M{XoUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTVwN{[4OFYh\|ryP	M4jh[3NCVkeHUh?=
MDA-MB-134-VI	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fY[GlEPTB;NT64O\|U{PiEQvF2=	NXz1SWhnW0GQR1XS
NB5	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvZUVZDUUN3ME21MlkzPDRizszN	MYHTRW5ITVJ?
GMS-10	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTVwOU[4OlEh\|ryP	NXT2cItmW0GQR1XS
CHP-212	NX;yUlZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXWTVFTUUN3ME22MlQ5OjZ5IN88US=>	MmrMV2FPT0WU
TE-11	M4C0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTZwNUWxPFIh\|ryP	MkT1V2FPT0WU
SW962	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTrTWM2OD14Lk[1O\|c1KM7:TR?=	MlvGV2FPT0WU
MZ2-MEL	NYjWOHBTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\SXZVNUUN3ME22MlgzODFzIN88US=>	MmDsV2FPT0WU
C-33-A	NED1WIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkD5TWM2OD14LkmxOlg5KM7:TR?=	MoDPV2FPT0WU
IGR-1	NFOzNm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TUdWlEPTB;Nj65O\|gzPiEQvF2=	M{KwZnNCVkeHUh?=
MOLT-4	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzOTWM2OD15LkG1OFA3KM7:TR?=	MVjTRW5ITVJ?
NCI-H1650	M{jkb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnX2TWM2OD15LkK3NFQ3KM7:TR?=	MYPTRW5ITVJ?
AsPC-1	NYjtT5dnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjYWpA2UUN3ME23MlI5PjB3IN88US=>	MnL5V2FPT0WU
SNU-C2B	NVX1cnZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVj5R4dkUUN3ME23MlI6PTdzIN88US=>	MnPIV2FPT0WU
MKN7	NHvleXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLKTWM2OD15LkO3NlM2KM7:TR?=	MXXTRW5ITVJ?
SW620	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnL4TWM2OD15LkO4NlA2KM7:TR?=	MUPTRW5ITVJ?
SK-MEL-28	Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzlZo5KUUN3ME23MlQxPzl6IN88US=>	Mo\YV2FPT0WU
TE-6	NF7GOolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIf4TlNKSzVyPUeuOFQ6ODhizszN	NFnjfVFUSU6JRWK=
D-263MG	NYX3Vmo3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\i[pBKSzVyPUeuOFU4PjJizszN	M2H6dHNCVkeHUh?=
NCI-H1355	M1;DWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTdwN{ewNlkh\|ryP	MnvoV2FPT0WU
DSH1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vySGlEPTB;Nz63PVc3OiEQvF2=	MVHTRW5ITVJ?
NCI-H460	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDsTWM2OD16LkCwOlk1KM7:TR?=	MXzTRW5ITVJ?
NCI-H1563	NELTbHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWL0c\|l4UUN3ME24MlA4PTB6IN88US=>	MoD5V2FPT0WU
SW948	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRThwMUC3OFQh\|ryP	M37FTXNCVkeHUh?=
LK-2	NHe5cnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRThwMUK4N\|Mh\|ryP	NV;0WWJrW0GQR1XS
HT-1080	NEm4cm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfGZot4UUN3ME24MlE{OTd3IN88US=>	MnXGV2FPT0WU
NCI-H441	NImwcWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPT[4RlUUN3ME24MlE6OyEQvF2=	Mn[1V2FPT0WU
HSC-4	NEjqbIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELnZVNKSzVyPUiuNlg4OiEQvF2=	MmfNV2FPT0WU
LXF-289	MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\EN5c4UUN3ME24MlM2QTR\|IN88US=>	NXfjepZkW0GQR1XS
MRK-nu-1	NVKwVVlqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnNTWM2OD16LkO2N\|A1KM7:TR?=	NFXtTpNUSU6JRWK=
no-11	Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjYdIRLUUN3ME24MlQ4OTN\|IN88US=>	MWXTRW5ITVJ?
SNU-387	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLHNnpoUUN3ME24MlY{OjR4IN88US=>	MYXTRW5ITVJ?
Detroit562	M2XWR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvOeW9vUUN3ME24Mlc2PDV3IN88US=>	NVrqSohjW0GQR1XS
SW954	M{Kzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzlPHJKSzVyPUiuO\|Y5OzJizszN	NHj5dHRUSU6JRWK=
P12-ICHIKAWA	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRThwN{i5OEDPxE1?	NH7KSIdUSU6JRWK=
TE-9	NXrjV5JRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HUWmlEPTB;OD64NVA3OiEQvF2=	M1r5bnNCVkeHUh?=
NB13	MnniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HjRWlEPTB;OD64N\|c6PiEQvF2=	NXvveGxGW0GQR1XS
BPH-1	NGTvNVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDaZmVKSzVyPUiuPFUxQDFizszN	NGjwcm5USU6JRWK=
KMOE-2	NUKyW\|RET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3IUZhMUUN3ME24Mlg4QDl{IN88US=>	MYLTRW5ITVJ?
RPMI-8402	NE\z[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXX6Sm5PUUN3ME24Mlg6QTJ4IN88US=>	M3X1VnNCVkeHUh?=
OVCAR-3	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRThwOUe3N\|Ih\|ryP	MnTJV2FPT0WU
NCI-H2196	NELJ[nhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jCUGlEPTB;OD65PFYxPiEQvF2=	M2D4bXNCVkeHUh?=
MZ7-mel	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{nQVmlEPTB;OT6wN\|Q3KM7:TR?=	M{PZXXNCVkeHUh?=
GP5d	M1XkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vI[GlEPTB;OT6wOlMyOyEQvF2=	NYHRe4N5W0GQR1XS
NCI-N87	MnTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTlwNES3N\|Eh\|ryP	NYXaZ41QW0GQR1XS
EW-16	MmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX[xOGhbUUN3ME25MlQ1QDR6IN88US=>	MUXTRW5ITVJ?
Calu-6	M{GyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PNPGlEPTB;OT60PVcxOyEQvF2=	M1fyOHNCVkeHUh?=
LC4-1	Ml;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYWwPXB7UUN3ME25MlYzPTdizszN	M{LtT3NCVkeHUh?=
CCRF-CEM	NVW5RYozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWi3bHdCUUN3ME25MlY5PzZ4IN88US=>	NV3xd5plW0GQR1XS
BC-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTlwN{i5PUDPxE1?	NV\lVmNPW0GQR1XS
NCI-SNU-16	NWjCWIgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXNcmFqUUN3ME25Mlc6PDl3IN88US=>	Mn6yV2FPT0WU
NCI-H28	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DmRWlEPTB;OT64OFk{OyEQvF2=	MXXTRW5ITVJ?
SBC-1	M{\5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTFyLkC3NkDPxE1?	M4fnfHNCVkeHUh?=
TUR	NIHYXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTFyLkG2OVch\|ryP	Mn7lV2FPT0WU
MDA-MB-231	NFjJfVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV7JR\|UxRTFyLkKxNVQh\|ryP	NF\XNmtUSU6JRWK=
C3A	NWjGemtlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mom3TWM2OD1zMD6zNVc6KM7:TR?=	MX7TRW5ITVJ?
SW1990	NV3kdXZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkOzTWM2OD1zMD6zNlgh\|ryP	MXrTRW5ITVJ?
NCI-H1993	MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTFyLkW2PVMh\|ryP	MnviV2FPT0WU
SK-CO-1	M{P2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3Lt[GlEPTB;MUCuO\|c4KM7:TR?=	M4nu[HNCVkeHUh?=
OAW-28	M1\W[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XZbGlEPTB;MUCuPVg5QCEQvF2=	MnfvV2FPT0WU
HN	NVPWSIhKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTFzLkGxN\|Eh\|ryP	M3n5XHNCVkeHUh?=
NCI-H1304	NXG0e3lnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2[xV2lEPTB;MUGuNVU4PiEQvF2=	NXqxe4trW0GQR1XS
Daoy	NHHLOZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTFzLkSzN\|Yh\|ryP	MY\TRW5ITVJ?
VA-ES-BJ	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTFzLkexPVUh\|ryP	Mn[2V2FPT0WU
MCF7	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLqTWM2OD1zMT64NVI3KM7:TR?=	NF;WRoRUSU6JRWK=
VM-CUB-1	MlLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\sTWM2OD1zMT65NFkyKM7:TR?=	MlfZV2FPT0WU
IPC-298	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTFzLkmzPFMh\|ryP	NYPwRYZxW0GQR1XS
NCI-H2126	NVnHbGtOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXkWpBPUUN3ME2xNk4xOjF6IN88US=>	MYXTRW5ITVJ?
OVCAR-8	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXvyVYI6UUN3ME2xNk4yOTRzIN88US=>	MYPTRW5ITVJ?
SJRH30	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmH6TWM2OD1zMj6yNlk6KM7:TR?=	NVfDdpYxW0GQR1XS
DMS-53	NUPZR\|FFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTF{LkK2OFkh\|ryP	MnTCV2FPT0WU
NCI-H322M	M{TKXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7hTZRKSzVyPUGyMlM{PTdizszN	MnjlV2FPT0WU
RVH-421	M{XTOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTF{LkS5NFQh\|ryP	NWD3bpo1W0GQR1XS
Raji	NVzkZod{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXWc\|JKSzVyPUGyMlYyPCEQvF2=	M4\Ve3NCVkeHUh?=
MDA-MB-415	M{jPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEW2d\|FKSzVyPUGyMlY1PDRizszN	M3fnbHNCVkeHUh?=
EFE-184	NVrGd4tYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTF{LkexNFYh\|ryP	M{TFZnNCVkeHUh?=
BFTC-909	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEmyeVhKSzVyPUGyMlkzPDdizszN	M4rGOXNCVkeHUh?=
BHY	NIHSZo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DwXWlEPTB;MUOuN\|M6KM7:TR?=	MWTTRW5ITVJ?
YKG-1	Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTF\|LkO3OFkh\|ryP	NIXOc2dUSU6JRWK=
EW-3	NIqzSolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETMfZVKSzVyPUGzMlcyPjNizszN	NFnHTHZUSU6JRWK=
HCC1143	NUj1UVVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2WwUWlEPTB;MUOuO\|Q{PyEQvF2=	NUK3XGt7W0GQR1XS
REH	NYK1OYpjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTF\|Lki5PFIh\|ryP	MmTCV2FPT0WU
CESS	NUTnfI1{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\XPVhKSzVyPUGzMlk1QDlizszN	MXzTRW5ITVJ?
EFM-19	M1:0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NITRVXNKSzVyPUG0MlEyOTJizszN	NWjid3JDW0GQR1XS
U031	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTF2LkSwPFUh\|ryP	MkfpV2FPT0WU
ES1	Ml;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV:4TVQ2UUN3ME2xOE41QDVzIN88US=>	MWHTRW5ITVJ?
HSC-3	NHfmZmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{CzSGlEPTB;MUSuOlIyPSEQvF2=	MlLTV2FPT0WU
LOXIMVI	NIix[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWr2eZlCUUN3ME2xOE44ODZ6IN88US=>	NVPaSnJvW0GQR1XS
A388	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfwb\|dmUUN3ME2xOE44PTV4IN88US=>	M4X4WHNCVkeHUh?=
KP-N-YS	NGjxWmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{j2NmlEPTB;MUSuO\|c{KM7:TR?=	NVTQc49jW0GQR1XS
Capan-2	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M325TWlEPTB;MUSuO\|g3KM7:TR?=	NY[1cZI6W0GQR1XS
SKG-IIIa	NGnvUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrMNXpKSzVyPUG0Mlg5PjJizszN	Ml36V2FPT0WU
HEL	MkGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlj0TWM2OD1zND64PVk4KM7:TR?=	NFTIeFVUSU6JRWK=
BEN	NWrHUFFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\IV5VKSzVyPUG0Mlk4PjZizszN	MXnTRW5ITVJ?
MC116	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlr0TWM2OD1zNT6xOVk6KM7:TR?=	NVSxdmZ4W0GQR1XS
IGROV-1	M3rDN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUK5VmZbUUN3ME2xOU4zOzF5IN88US=>	M371e3NCVkeHUh?=
NCI-H1648	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPZdYVKSzVyPUG1MlU{ODVizszN	NGfZT5RUSU6JRWK=
ABC-1	M4\hVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vUfWlEPTB;MUWuPFA{OyEQvF2=	NY[3OGZOW0GQR1XS
EW-18	NESzXnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfNTWM2OD1zNT65PVc6KM7:TR?=	NUC3N\|h7W0GQR1XS
BC-3	NYK0e5JPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDpTWM2OD1zNj6wOVYzKM7:TR?=	NXq2b2NlW0GQR1XS
NCI-H1437	NHfjXZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXz4dYdZUUN3ME2xOk4xPjZ5IN88US=>	NX20[4NjW0GQR1XS
SCC-15	M1HKT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjoeXNKSzVyPUG2MlI5OjVizszN	M2HSN3NCVkeHUh?=
TT	MmPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;EdGlEPTB;MU[uOVg5QCEQvF2=	MULTRW5ITVJ?
KINGS-1	MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI[zRWxKSzVyPUG2MlgzPzNizszN	MnfMV2FPT0WU
C32	MnPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1n0UWlEPTB;MU[uPVcyPyEQvF2=	Mk\0V2FPT0WU
SBC-5	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTF5LkG0O\|kh\|ryP	M1WwcXNCVkeHUh?=
NB1	NHnvXGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1j4cmlEPTB;MUeuN\|E5QCEQvF2=	M33DNnNCVkeHUh?=
EB-3	NYjGNmtMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTF5LkW3OkDPxE1?	M1zVNXNCVkeHUh?=
NCI-H748	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnD[ms2UUN3ME2xO{44ODN3IN88US=>	MoXUV2FPT0WU
IST-SL1	NHS4ZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTF5Lke1NlYh\|ryP	NFTBXnNUSU6JRWK=
WM-115	NGOzd2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoizTWM2OD1zNz64NFg2KM7:TR?=	NXrxSGozW0GQR1XS
NCI-H226	NF6wUXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrXTWM2OD1zNz65OVQ3KM7:TR?=	MUjTRW5ITVJ?
CAL-33	NX;ySm4{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfVTWM2OD1zOD6yO\|gyKM7:TR?=	NFm1VmZUSU6JRWK=
SCC-4	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2f6RmlEPTB;MUiuN\|IzQSEQvF2=	NHv4N2dUSU6JRWK=
RMG-I	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnf1TWM2OD1zOD62PVQ4KM7:TR?=	MmTCV2FPT0WU
KOSC-2	M3f1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrEeGtKSzVyPUG4Mlc4PDZizszN	NWrCTXZoW0GQR1XS
A2058	M4HST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTF6LkiyOVUh\|ryP	NFLFPXBUSU6JRWK=
HCC70	MkT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PKSmlEPTB;MUmuN\|g6PCEQvF2=	NWLNT2Z[W0GQR1XS
C2BBe1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rVe2lEPTB;MUmuOFE1QCEQvF2=	MlPRV2FPT0WU
NCI-H650	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfz[YNKSzVyPUG5MlU5QTlizszN	NV;2TnhxW0GQR1XS
CAL-72	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrLfFVIUUN3ME2xPU43PzN5IN88US=>	MYLTRW5ITVJ?
L-363	MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fa[GlEPTB;MkCuNFIyOiEQvF2=	Mo\sV2FPT0WU
SNU-423	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTJyLkGwOFMh\|ryP	MnfSV2FPT0WU
PLC-PRF-5	NFHF[G5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTVTWM2OD1{MD6zPVA3KM7:TR?=	NH7sZpdUSU6JRWK=
SW1463	NXTEfYl3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XO[2lEPTB;MkCuOFUzPSEQvF2=	Moe5V2FPT0WU
769-P	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHkTWM2OD1{MD62O\|Y6KM7:TR?=	MVvTRW5ITVJ?
DMS-79	NIC4VWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTh[mRKSzVyPUKwMlg1QSEQvF2=	NFfHbllUSU6JRWK=
Saos-2	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXf3[oNIUUN3ME2yNE46PTV4IN88US=>	MlW0V2FPT0WU
CHP-126	NHKxdJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2Twb2lEPTB;MkGuOFQ3OiEQvF2=	NG\JPZFUSU6JRWK=
SW837	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfrO5ZKSzVyPUKxMlQ6OzlizszN	MVTTRW5ITVJ?
SHP-77	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPBTWM2OD1{MT62NVIzKM7:TR?=	MlraV2FPT0WU
DB	M{PwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{KzPWlEPTB;MkGuOlE1OiEQvF2=	NIOwbmVUSU6JRWK=
ES5	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NED0[nhKSzVyPUKxMlY5PjRizszN	M{HoSHNCVkeHUh?=
COR-L23	M3zYNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInvUGxKSzVyPUKxMlgxPTFizszN	NXryR3g3W0GQR1XS
KU-19-19	MkTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYi1ZnpsUUN3ME2yNU45QTh{IN88US=>	M{fkNnNCVkeHUh?=
T84	NFHZUVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1ftSWlEPTB;MkGuPVgyQSEQvF2=	NWS4d5R6W0GQR1XS
NCI-H630	Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnNOXNKSzVyPUKyMlU{PjNizszN	M4e1fHNCVkeHUh?=
LU-165	NFz2ZlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTJ{LkW1OEDPxE1?	M37RU3NCVkeHUh?=
COLO-792	Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTDVWp{UUN3ME2yNk44OTFzIN88US=>	NF;FSohUSU6JRWK=
CAL-62	NETkV49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUGzOpBuUUN3ME2yNk44PTF5IN88US=>	NHS0T5pUSU6JRWK=
HCE-T	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTJ{Lki2NFYh\|ryP	NUOyPI1OW0GQR1XS
BB65-RCC	M4THW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{P3VGlEPTB;MkOuNFM1PCEQvF2=	MoHzV2FPT0WU
SiHa	NIXDPG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NET6UodKSzVyPUKzMlM6PjhizszN	NFzyO49USU6JRWK=
NCI-H2081	Mo\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3oTWM2OD1{ND6wOlQyKM7:TR?=	MmLiV2FPT0WU
U251	NEG0dlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HpXWlEPTB;MkSuNFY3QCEQvF2=	MWDTRW5ITVJ?
LoVo	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTJ2LkmyPFIh\|ryP	NWPoSppqW0GQR1XS
GCIY	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37KUWlEPTB;MkWuNlg4PyEQvF2=	MlPmV2FPT0WU
NUGC-3	MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTJ3LkOzNVYh\|ryP	NYXIXnM5W0GQR1XS
LNCaP-Clone-FGC	MnTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{flS2lEPTB;MkWuN\|Q6QCEQvF2=	M3H5VXNCVkeHUh?=
PA-1	NHfaUmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3i[4tKSzVyPUK1MlY5OzNizszN	NXLRPI9HW0GQR1XS
OE33	M17EZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHY[HRKSzVyPUK1MlY5PTNizszN	MoTBV2FPT0WU
HT-29	NEL5N3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTJ3Lke4O\|kh\|ryP	MVjTRW5ITVJ?
RCM-1	MmrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrCbnBsUUN3ME2yOU46PjV4IN88US=>	MVXTRW5ITVJ?
NCI-H1522	MmKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTqZo1NUUN3ME2yOU46QTFzIN88US=>	NInFW2VUSU6JRWK=
LB373-MEL-D	NX3wUHBbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17Dc2lEPTB;Mk[uNVcxQCEQvF2=	MX3TRW5ITVJ?
NCI-H1436	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\ETJJQUUN3ME2yOk4zPzN6IN88US=>	NEX5cVZUSU6JRWK=
COLO-824	NIf5S5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHoWHZUUUN3ME2yOk41ODB{IN88US=>	MVvTRW5ITVJ?
CP50-MEL-B	NX\FXVg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTJ4LkW2O\|Uh\|ryP	NYrPOFY6W0GQR1XS
EGI-1	NWDZblhKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTJ5LkK2PVgh\|ryP	MoPWV2FPT0WU
LAN-6	NUPsNlJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTJ5LkO1PVgh\|ryP	NU\tOmtXW0GQR1XS
GAK	M17VTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF6ze4hKSzVyPUK3MlQzOjVizszN	MYnTRW5ITVJ?
MDA-MB-175-VII	NHfyOYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYWzS2pWUUN3ME2yO{42ODV\|IN88US=>	NVTNPGY6W0GQR1XS
JVM-2	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\4TWM2OD1{Nz62OlIzKM7:TR?=	M33UdXNCVkeHUh?=
UACC-257	NGPzNGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTJ5Lk[4O\|gh\|ryP	Mnu1V2FPT0WU
SW1783	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2P6eGlEPTB;MkeuO\|c5OyEQvF2=	NUfvXI12W0GQR1XS
HT-3	NFzMVYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTJ6LkKxOlYh\|ryP	MlPuV2FPT0WU
RL	NIq0eZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHId4ZKSzVyPUK4MlU6OTFizszN	MmXGV2FPT0WU
TK10	NX;4cYw5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTJ6Lk[1N\|Uh\|ryP	NXzVcZQ5W0GQR1XS
HT55	MorkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\ycmlEPTB;MkmuNFU3PSEQvF2=	NV3j[FJKW0GQR1XS
BT-20	MkHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\ZOYFXUUN3ME2yPU4xPTh4IN88US=>	NV;YeYt7W0GQR1XS
TGBC24TKB	NV62b\|RYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTJ7LkG4N\|Eh\|ryP	NU\pU\|VrW0GQR1XS
HSC-2	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTJ7LkOwNFEh\|ryP	Mn\BV2FPT0WU
COLO-205	M13B[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTJ7LkO5OFQh\|ryP	MXHTRW5ITVJ?
GT3TKB	NUPDVndyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTJ7Lk[4O\|ch\|ryP	NYDTdFR[W0GQR1XS
T47D	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fVPGlEPTB;MkmuPFU5OiEQvF2=	MoHjV2FPT0WU
OMC-1	NF7nUmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPocpNVUUN3ME2zNE4yQTF7IN88US=>	NIfCNY5USU6JRWK=
PFSK-1	NUO2b2V1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nkXmlEPTB;M{GuNlY2QSEQvF2=	Mn3DV2FPT0WU
JEG-3	NIW0RXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVWzR3dUUUN3ME2zNU4{PTZzIN88US=>	NHy1O3JUSU6JRWK=
RD	NUXl[mpDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDlTWM2OD1\|MT61NVE2KM7:TR?=	NGTtTVlUSU6JRWK=
NCI-H64	M3fxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEK0eYNKSzVyPUOyMlQyPzlizszN	NH;FPHFUSU6JRWK=
DMS-114	M1jBUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4S3RmlEPTB;M{KuOFE5OiEQvF2=	MkO3V2FPT0WU
NCI-H661	NXrUTIlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;icVhJUUN3ME2zNk43PTBzIN88US=>	MXrTRW5ITVJ?
CAL-148	MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHqwNWtKSzVyPUOyMlY3PjVizszN	MWfTRW5ITVJ?
HuP-T3	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTN{LkmzN\|gh\|ryP	MULTRW5ITVJ?
ES4	MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13Gd2lEPTB;M{OuNVcxPSEQvF2=	Ml;EV2FPT0WU
Ca9-22	NU[4S5V4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTN\|LkS2NFEh\|ryP	NGToSYVUSU6JRWK=
LP-1	NFH2[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTN2LkC5JO69VQ>?	M2DFT3NCVkeHUh?=
AU565	MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTN2LkWwOlkh\|ryP	MkjmV2FPT0WU
MDA-MB-453	NHLQOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3OxZWlEPTB;M{WuNVQzPiEQvF2=	NUXwe4VZW0GQR1XS
SNU-C1	NWX4R29yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\XbWp[UUN3ME2zOU4yPzFizszN	MkTEV2FPT0WU
SW13	M2rKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnRNpNwUUN3ME2zOU41ODd4IN88US=>	NV3lNo85W0GQR1XS
NCI-H2122	NYPzNmdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PN[WlEPTB;M{WuOVU6QCEQvF2=	NXfmOVFLW0GQR1XS
NCI-H1395	NVPnXnF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTN3Lk[2PVEh\|ryP	NVvO[VNrW0GQR1XS
J-RT3-T3-5	M2fUbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvMW4NKSzVyPUO2MlAzQTRizszN	MlT5V2FPT0WU
COR-L279	M3PmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\DO3Y2UUN3ME2zOk4yQThzIN88US=>	NV75ZYF[W0GQR1XS
ATN-1	NYe1XmRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDiOGpKSzVyPUO2Mlg2OTZizszN	NVX6T49iW0GQR1XS
HCC2998	MlvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;KTWM2OD1\|Nj64OVcyKM7:TR?=	NGPrbVhUSU6JRWK=
UM-UC-3	NF7wNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV61fmFDUUN3ME2zOk45Pjd3IN88US=>	NHvsNVJUSU6JRWK=
DV-90	MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYfZ[4V5UUN3ME2zOk46ODZ5IN88US=>	MYXTRW5ITVJ?
ES8	Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MknXTWM2OD1\|Nj65N\|E5KM7:TR?=	NHfD[VJUSU6JRWK=
YAPC	NWLYV3N5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHaTWM2OD1\|Nj65OlU1KM7:TR?=	NHXFW\|hUSU6JRWK=
HCC1599	M{LtZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2WzNGlEPTB;M{euNVYyQCEQvF2=	NYHmOHE6W0GQR1XS
UMC-11	M4K4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXtR41tUUN3ME2zO{4zPTB\|IN88US=>	M3vJVHNCVkeHUh?=
THP-1	NFvE[ZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDxRYl2UUN3ME2zO{4zQDZ6IN88US=>	MWrTRW5ITVJ?
OCUB-M	M{fl[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETQPIVKSzVyPUO3MlI5QTFizszN	MYnTRW5ITVJ?
NCI-H1693	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTN5LkOyN\|Mh\|ryP	MUHTRW5ITVJ?
NCI-H345	NHrET\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTN5LkO2NlQh\|ryP	NFjaNVRUSU6JRWK=
COLO-800	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnm3TWM2OD1\|Nz61Olch\|ryP	M4i3dnNCVkeHUh?=
COLO-320-HSR	M1jBXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLFfXdKUUN3ME2zPE4{PDl{IN88US=>	MXrTRW5ITVJ?
NCI-H596	NUTDb4F{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojlTWM2OD1\|OD60OFg6KM7:TR?=	NIfLfGNUSU6JRWK=
NCI-H187	NVeyUnZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nROWlEPTB;M{iuO\|M1PCEQvF2=	NXTSPXM5W0GQR1XS
ECC4	NHP6fplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HldmlEPTB;M{muNFgyPCEQvF2=	NVn4dYE{W0GQR1XS
KP-4	NUDnPHU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlr5TWM2OD1\|OT6xNlM2KM7:TR?=	MUXTRW5ITVJ?
NCI-H2227	Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DDWWlEPTB;M{muN\|k1QSEQvF2=	M{LY[3NCVkeHUh?=
22RV1	NXHOeHlYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTN7LkizPVgh\|ryP	Mk\kV2FPT0WU
SAS	NXGzSJJqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFP1WodKSzVyPUSwMlA6PiEQvF2=	NIDuZYxUSU6JRWK=
PANC-10-05	NF3UW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTRyLkG4Nlgh\|ryP	NUHIWG9kW0GQR1XS
MDA-MB-468	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnnSZZKSzVyPUSwMlU{PDZizszN	MnixV2FPT0WU
RPMI-7951	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrGbndKSzVyPUSxMlIxPzVizszN	MULTRW5ITVJ?
BB49-HNC	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTRzLkKxO\|kh\|ryP	MmnHV2FPT0WU
23132-87	NFH6TXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jRTWlEPTB;NEGuNlc{OiEQvF2=	MYPTRW5ITVJ?
HCC1569	NVzhdmRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnmT29xUUN3ME20NU4zQDh3IN88US=>	M{\3dHNCVkeHUh?=
CP66-MEL	Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PMT2lEPTB;NEKuNVg5PiEQvF2=	MXHTRW5ITVJ?
K-562	NH7iOHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTR{LkK4OVQh\|ryP	M2T0OXNCVkeHUh?=
OCI-AML2	M3nWbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrFTWM2OD12Mj64PVc1KM7:TR?=	Mm\sV2FPT0WU
SW756	NGizUphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF6zNpBKSzVyPUSzMlA{QDhizszN	M1fyVXNCVkeHUh?=
M14	NFTsTmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWH5VJR2UUN3ME20N{4{OTh7IN88US=>	MXTTRW5ITVJ?
NCI-H1623	NELFWFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{T6bmlEPTB;NEOuOFY1KM7:TR?=	Mn21V2FPT0WU
KNS-81-FD	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvvO3R[UUN3ME20N{44PjJizszN	NVOxU255W0GQR1XS
TGBC1TKB	M1y5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7UbohRUUN3ME20N{46ODl7IN88US=>	M2K5cnNCVkeHUh?=
RERF-LC-MS	NHr5PYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LCWmlEPTB;NEOuPVI5OSEQvF2=	MVrTRW5ITVJ?
PC-3	NY[zSJhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGj1coNKSzVyPUS0MlQ{PDdizszN	MnnmV2FPT0WU
HuP-T4	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\vTo5KSzVyPUS0MlQ1PzRizszN	NIT4T\|JUSU6JRWK=
NCI-H510A	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\pfXRIUUN3ME20OE44ODhizszN	M4rhe3NCVkeHUh?=
LB2518-MEL	MnnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPnWIpyUUN3ME20OE44QTN5IN88US=>	NELmXFFUSU6JRWK=
TE-5	M2XCe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFn2eYNKSzVyPUS1Mlk2QDFizszN	NHfXOVNUSU6JRWK=
EW-24	MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTR4LkG3NlMh\|ryP	Ml;pV2FPT0WU
LB647-SCLC	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPlTWM2OD12Nj6yNVU2KM7:TR?=	MkTQV2FPT0WU
NCI-H524	NFLyPI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7FTWM2OD12Nj63NVg2KM7:TR?=	Ml3yV2FPT0WU
EW-11	Mmf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXL0U5FEUUN3ME20Ok46Ozd\|IN88US=>	NHLwVG9USU6JRWK=
KALS-1	MmrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPoOHNVUUN3ME20O{4zODZ4IN88US=>	M3jtOnNCVkeHUh?=
BT-474	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\iRYdKUUN3ME20O{41OjF4IN88US=>	NXOwSIYzW0GQR1XS
SK-N-AS	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTLW4tNUUN3ME20O{45QDhizszN	NFrXdIZUSU6JRWK=
HCC2157	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvBTWM2OD12OD6wO\|Yh\|ryP	NHLTfJhUSU6JRWK=
HCC1954	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrncm5WUUN3ME20PE4yPzB2IN88US=>	NIDHRWVUSU6JRWK=
FADU	MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mme1TWM2OD12OD6zNFMyKM7:TR?=	MmrCV2FPT0WU
S-117	M2fqXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm[xTWM2OD12OD6zPFE2KM7:TR?=	M3vYU3NCVkeHUh?=
LS-1034	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zIcWlEPTB;NEiuO\|A3PyEQvF2=	Mlq4V2FPT0WU
CAMA-1	NUTFO\|R6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DTcGlEPTB;NEmuOVU1OyEQvF2=	M4HLfHNCVkeHUh?=
LU-134-A	MlzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTR7LkiwPFUh\|ryP	NWq2WWg4W0GQR1XS
NCI-H1838	MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTR7LkiwPFch\|ryP	MnfuV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pSrc / Src / pPlcg / Plcg / pStat5 / Stat5 ; PubMed: 22781593 Leukemia In (B) inhibition of Src, Plcg and Stat5 was seen in MLNAF cell lines treated with Ponatinib; ZNF112 expresses ZMYM2–FGFR1, CEP2A and CEP5A cells express CEP110–FGFR1 and BBC2 expresses BCR–FGFR1. pFGFR1(pY20) / FGFR1; PubMed: 22781593 Leukemia Western blot analysis, using various antibodies specific for downstream targets of FGFR1, demonstrates that Ponatinib inhibits the activation of Plcg and Src as a result of inhibiting the FGFR1 fusion kinase in human KG1 cells. cleaved caspase-3 / cleaved caspase-7 / BAX / Bcl-2; PubMed: 30959969 Molecules Western blot analysis of cleaved caspase-3, cleaved caspase-7, Bax, Bcl-2, and β-Tubulin (control) in treated cells. p-Rb(S807/811) / Rb / CDK4 / CDK6 / Cyclin D1 / CDK2 / Cyclin E1; PubMed: 30959969 Molecules Western blot analysis of Rb/p-Rb, CDK4, CDK6, Cyclin D1, CDK2, Cyclin E1, and β-Tubulin (control) in the SK-Hep-1 and SNU-423 cells treated with ponatinib. RAD51; PubMed: 30959969 Molecules The effect of ponatinib on the concentration of Rad51 in SK-Hep-1 and SNU-423 cells. p-MEK / MEK / p-ERK / ERK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of Mek and Erk. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. c-Jun / p-JNK(T183/Y185) / JNK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of JNK and c-Jun. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. p-p38 MAPK / p38 MAPK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of p38. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. p-JAK2 / JAK2 / p-STAT3 / STAT3; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of Jak2, and Stat3. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. PI3K p85 / p-PI3K / p-PDK1 / PDK1 / p-mTOR / mTOR; PubMed: 30959969 Molecules Effects of ponatinib on the protein concentration and phosphorylation of PI 3-kinase, PDK1, Akt, and mTOR in HCC cells. p-PDGFRα / PDGFRα; PubMed: 24472312 Mol Cancer Ponatinib inhibited phosphorylation of PDGFRα in a concentration-dependent manner. EOL-1 and BaF3-WT or -T674I FIP1L1-PDGFRα cells were exposed to escalating concentrations of ponatinib for 24 h. PARP / Caspase-3 / Active Caspase-3; PubMed: 24472312 Mol Cancer The concentration- (for 24 h) and time-dependent (1 nM for EOL-1, 300 nM for BaF3-WT and -T674I FIP1L1-PDGFRα cells) cleavage of PARP and caspase-3 triggered by ponatinib was analyzed by immunoblotting. AIF / Cyto C ; PubMed: 24472312 Mol Cancer Ponatinib elicited release of AIF and cytochrome c into the cytosol. Cells were treated with 1 nM ponatinib for the indicated durations and the cytosolic fraction was extracted with digitonin buffer. Levels of AIF and Cytochrome c (Cyto c) were detected by immunoblotting. Mcl-1 / Survivin / Bcl-Xl / XIAP / Bax / Bcl-2 / Bim; PubMed: 24472312 Mol Cancer Immunoblotting of apoptosis-related proteins in CEL cells after treatment for 24 h. β-catenin ; PubMed: 24472312 Mol Cancer Ponatinib concentration-dependently lowered β-catenin. EOL-1 cells were incubated with ponatinib for 24 h, and cytoplasmic and nuclear extracts were determined by immunoblotting. β-catenin; PubMed: 24472312 Mol Cancer Analysis of β-catenin localization. EOL-1 cells were pretreated with 1 nM ponatinib for 24 h, immunofluorescence analysis was performed with anti-β-catenin. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). ABL; PubMed: 19878872 Cancer Cell In vitro [γ-32P]-ATP autophosphorylation of full-length (A) ABL or (B) ABLT315I kinase treated with AP24534, imatinib, nilotinib, or dasatinib. After incubation of tyrosine-dephosphorylated enzyme with the indicated inhibitor in the presence of [γ-32P]-ATP and separation by SDS-PAGE, signal intensity was measured by autoradiography.	22781593 30959969 24472312 19878872
Growth inhibition assay	Cell viability; PubMed: 30174789 Oncotarget (A) Effect of Ponatinib on basal viability of HUVECs. The cells were treated with Ponatinib at indicated concentrations or 0.1% DMSO (vehicle control) for 24 h.	30174789

体内研究

Ponatinib抑制取自FLT3-ITD阳性AML病人的原代白血病细胞，而不抑制表达阴性FLT3的AML病人的白血病细胞。^[3]

激酶实验：^[1]	- 合并激酶实验: 通过同质时间分辨荧光共振能量转移法(TR-FRET)，使用纯化的人类野生型ABL激酶，T315I突变型ABL激酶，及生物素化的磷酸激酶底物肽: 生物素-EKKMAAEAIYAAPFAK-NH2，测定野生型ABL和T315I突变型ABL活性的抑制激酶反应在全LANCE激酶buffer (LKB)中进行，LKB包括20 mM NaHEPES（pH 为7.4）, 0.1 mg ⁄ mL BSA, 1 mM ATP, 10 mM MgCl₂, 及0.41 mM DTT，在提前用1% BSA（溶于PBS）包被的96孔板上4^oC下过夜。用于激酶反应，Ponatinib稀释物和野生型ABL, T315I突变型ABL (40 pM), 及底物肽(50 nM), 在室温下温育1小时（T315I突变型ABL）或2小时（野生型ABL）。加入15 nM 抑制剂, 6 nM 铕标记的磷酸酪氨酸抗体（磷酸化位点在第66为酪氨酸上），及60 nM 别藻蓝素标记的链酶亲和素，终止反应。实验板在室温下黑暗温育20分钟，使用Wallac Victor2V读数器读取615和665nm处的荧光值。在孔中数据平均值中插入抑制剂的3倍连续稀释液，再读取665nm处荧光值，计算IC50值。
细胞实验：^[1]	- 合并 Cell lines: Ba ⁄ F3细胞 Concentrations: 0-625 nM, 和0-10 µM Incubation Time: 72小时 Method: Ba/F3细胞系按每孔4×10³个细胞分布在96孔板上(4×10³)，和梯度浓度Ponatinib温育72小时。Ponatinib浓度范围为: 0-625 nM 作用于表达BCR-ABL细胞，0-10 µM 用于测定BCR-ABL阴性细胞。使用MTS实验测定细胞增殖，取三次平行实验平均值测定IC50值。 (Only for Reference)
动物实验：^[3]	- 合并 Animal Models: 皮下植入MV4-11细胞移植瘤(1×10⁷，50%基质胶中) 的雌性CB.17 SCID鼠 Dosages: 每天处理一次，持续4周 Administration: 口服饲喂处理 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	30 mg/mL (56.33 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 1% CMC Na	30mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Ponatinib (AP24534) SDF

分子量	532.56
化学式	C₂₉H₂₇F₃N₆O
CAS号	943319-70-8
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04160546	Recruiting	Drug: Ponatinib 15 MG\|Drug: Acetylsalicylic acid 100 MG	Chronic Myeloid Leukemia Chronic Phase	Fundacion CRIS de Investigación para Vencer el Cáncer\|Incyte Biosciences UK\|Apices Soluciones S.L.	January 17 2020	Phase 2
NCT04070443	Recruiting	Drug: Ponatinib\|Drug: Imatinib	Philadelphia Chromosome Positive CML\|BCR-ABL Positive Chronic Myelogenous Leukemia	Centre Leon Berard	November 13 2019	Phase 2
NCT03934372	Recruiting	Drug: Ponatinib	Acute Myeloid Leukemia\|Accelerated Phase Chronic Myeloid Leukemia\|Blast Phase Chronic Myeloid Leukemia\|Chronic Phase Chronic Myeloid Leukemia\|Acute Lymphoblastic Leukemia\|Acute Lymphocytic Leukemia\|Leukemia\|Lymphoma\|Solid Tumors	Incyte Biosciences International Sàrl\|Incyte Corporation	November 22 2019	Phase 1\|Phase 2
NCT03895671	Recruiting	Drug: Ponatinib\|Drug: Azacitidine	CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE\|CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS	Versailles Hospital	June 19 2019	Phase 2
NCT03690115	Recruiting	Drug: Ponatinib 30 MG	Leukemia Myeloid Acute	Versailles Hospital	December 12 2018	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
Is the pre-solubilized inhibitor suitable for in vivo whole animal studies? Whether the solvent contains any non-DMSO stabilizer?
回答：
Our 10mM Ponatinib in DMSO solution is in pure DMSO and there is not other stabilizer added. You can use it for animal study. The vehicle we suggest for Ponatinib is: 30% PEG400/0.5% Tween80/5% Propylene glycol. It is a milky suspension used for oral gavage.

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

选择性强的Bcr-Abl抑制剂

Nilotinib (AMN-107) : Bcr-Abl-selective, IC50<30 nM.
活性最高的Bcr-Abl抑制剂

GZD824 : Bcr-Abl(WT), IC50=0.34 nM; Bcr-Abl(T315I), IC50=0.68 nM.
FDA批准的Bcr-Abl抑制剂

Dasatinib : Approved by FDA for CML and Ph+ ALL.
最新的Bcr-Abl抑制剂

GZD824 : Orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.

研究领域

产品类型

Ponatinib (AP24534)

客户使用Selleck生产的Ponatinib (AP24534)发表文献95篇：

产品安全说明书

Bcr-Abl抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Ponatinib (AP24534) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-05-15)

技术支持

常见问题及建议解决方法

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

相关Bcr-Abl产品